The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells

Leukemia

Volumn 18, Issue 8, 2004, Pages 1364-1372

  Srinivasan, R S ^a   Nesbit, J B ^a   Marrero, L ^b   Erfurth, F ^c   LaRussa, V F ^a   Hemenway, C S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fusion genes; Infant leukemia; MLL; Peptide therapeutics

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN AF4; PROTEIN AF9; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; FUSION GENE; GENE DISRUPTION; GENE EXPRESSION; GENE MAPPING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

EID: 4344621639     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403415     Document Type: Article

References (44)

1. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox gene expression and segmental identity in Mll-mutant mice. Nature 1995; 378: 505-508.
2. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian trithorax group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci USA 1998; 95: 10632-10636.
3. Hess JL, Yu BD, Li B, Hanson R, Korsmeyer SJ. Defects in yolk sac hematopoiesis in Mll-Null embryos. Blood 1997; 90: 1799-1806.
4. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10: 1107-1117.
5. Rowley JD. The critical role of chromosome translocations in human leukemias. Annu Rev Genet 1998; 32: 495-519.
6. Li Q, Frestedt JL, Kersey JH. AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments. Blood 1998; 92: 3841-3847.
7. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695-5707.
8. So CW, Cleary ML. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Blood 2003; 101: 633-639.
9. Zeisig BB, Schreiner S, Garcia-Cuellar MP, Slany RK. Transcriptional activation is a key function encoded by MLL fusion partners. Leukemia 2003; 17: 359-365.
10. Felix CA, Lange BJ, Chessells JM. Pediatric acute lymphoblastic leukemia: challenges and controversies in 2000. Hematology (Am Soc Hematol Educ Program) 2000, 285-302.
11. Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700-706.
12. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122-129.
13. Isnard P, Coré N, Naquet P, Djabali M. Altered lymphoid development in mice deficient for the mAF4 proto-oncogene. Blood 2000; 96: 705-710.
14. Collins EC, Appert A, Ariza-McNaughton L, Pannell R, Yamada Y, Rabbitts TH. Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with AF9 after chromosomal translocation in leukemia. Mol Cell Biol 2002; 22: 7313-7324.
15. Doty RT, Vanasse GJ, Disteche CM, Willerford DM. The leukemia-associated gene Mlltl/ENL: characterization of a murine homolog and demonstration of an essential role in embryonic development. Blood Cells Mol Dis 2002; 28: 407-417.
16. Erfurth F, Hemenway CS, de Erkenez AC, Domer PH. MLL fusion partners AF4 and AF9 interact at subnuclear foci. Leukemia 2004; 18: 92-102.
17. Srinivasan RS, de Erkenez AC, Hemenway CS. The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor. Oncogene 2003; 22: 3395-3406.
18. Hemenway CS, de Erkenez AC, Gould GC. The polycomh protein MPc3 interacts with AF9, and MLL fusion partner in t(9;11)(p22;q23) acute leukemias. Oncogene 2001; 20: 3798-3805.
19. Domer PH, Fakharzadeh SS, Chen C, Jockel J, Johansen L, Silverman GA et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci USA 1993; 90: 7884-7888.
20. Taki T, Kano H, Taniwaki M, Sako M, Yanagisawa M, Hayashi Y. AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23). Proc Natl Acad Sci USA 1999; 96: 14535-14540.
21. von Bergh AR, Beverloo HB, Rombout P, van Wering ER, van Weel MH, Beverstock GC et al. LAF4, an AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia. Genes Chromosomes Cancer 2002; 35: 92-96.
22. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-10450.
23. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 1985; 65: 21-31.
24. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987; 70: 192-199.
25. Cohen A, Grunberger T, Vanek W, Dube ID, Doherty PJ, Letarte M et al. Constitutive expression and role in growth regulation of interleukin-1 and multiple cytokine receptors in a biphenotype leukemia cell line. Blood 1991; 78: 94-102.
26. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972; 49: 891-895.
27. Koziner B, Stavnezer J, Al-Katib A. Surface immunoglobulin light-chain expression by the 'common' ALL cell line REH. Clin Immunol Immunopathol 1985; 37: 135-141.
28. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171-176.
29. Kersey JH, Wang D. Oberto M. Resistance of t(4;11)(MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanisms for extensive extramedullary accumulation of cells and poor prognosis. Leukemia 1998; 12: 1561-1564.
30. Dorrie J, Schuh W, Keil A, Bongards E, Greil J, Fey GH et al. Regulation of CD95 expression and CD95-mediated cell death by interferon-gamma in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Leukemia 1999; 13: 1539-1547.
31. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
32. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003; 278: 585-590.
33. Felix C, Lange BJ. Leukemia in infants. Oncologist 1999; 4: 225-240.
34. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445-455.
35. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33.
36. Chessells JM, Harrison CJ, Kempski H, Webb DK, Wheatley K, Hann IM et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood leukaemia working party. Leukemia 2002; 16: 776-784.
37. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
38. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
39. Armstrong SA, Kung AL, Mahon ME, Silverman LB, Stam RW, Den Boer ML et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-183.
40. Domer PH, Fakharzadeh SS, Chen C, Jockel J, Johansen L, Silverman GA et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc Natl Acad Sci USA 1993; 90: 7884-7888.
41. Rubnitz JE, Morrissey J, Savage PA, Cleary ML. ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells. Blood 1994; 84: 1747-1752.
42. Gecz J, Gedeon AK, Sutherland GR, Mulley JC. Identification of the gene FMR2 associated with FRAXE mental retardation. Nat Genet 1996; 13: 105-108.
43. Gu Y, Shen Y, Gibbs R, Nelson DL. Identification of FMR2, a novel gene associated with the FRAXF CCG repeat and CpG island. Nat Genet 1996; 13: 109-113.
44. Ma C, Staudt LM. LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. Blood 1996; 87: 734-745.